Bristol Myers Squibbvs.Zoetis
BMY vs ZTS · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Bristol Myers Squibb is about 4.4× larger than Zoetis by market cap; Zoetis trades at the lower P/E (11.5 vs 14.2); year to date, Bristol Myers Squibb leads (+24.7% vs −38.7%).
Side by side
| BMY | ZTS | |
|---|---|---|
| Market cap | $132B | $30.2B |
| Price | $67.92 | $77.29 |
| Today | +1.0% | +0.2% |
| Return YTD | +24.7% | −38.7% |
| Return 1Y | +40.4% | −50.7% |
| P/E | 14.2 | 11.5 |
| P/S | 2.7 | 3.2 |
| P/B | 5.9 | 9.6 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Bristol Myers SquibbBMY
Opdivo made the company's name in oncology. Immunology and haematology fill out the portfolio, with neuroscience coming through the pipeline.
Full BMY profile →ZoetisZTS
Spun out of Pfizer in 2013 to sell animal medicines and vaccines. Simparica handles parasites while Librela and Solensia treat pain, with pets on one side of the business and livestock on the other.
Full ZTS profile →More BMY & ZTS comparisons
Other head-to-heads in the Big pharma segment.